Business Context and Reporting Period
This Form 8-K, dated February 2, 2018, reports on Becton, Dickinson and Company (BD) following the completion of its acquisition of C.R. Bard, Inc. on December 29, 2017. The filing announces a restructuring of BD's reportable business segments effective with the second fiscal quarter of 2018 to integrate Bard's operations.
Key Financial Metrics and Segment Changes
The filing does not provide specific GAAP revenue, profit, cash flow, or debt figures for the current period. Instead, it focuses on the methodology for presenting "adjusted comparable revenues," a non-GAAP measure designed to show what combined revenues would have been if the Bard acquisition occurred at the start of fiscal 2016.
New Segment Structure
- BD Interventional (New Segment): Includes the majority of Bard's product offerings and select BD Medical products. It comprises three units: Surgery (hernia repair, biosurgery, infection prevention), Peripheral Intervention (vascular products, catheters, stents), and Urology and Critical Care (urology products, cancer diagnostics).
- BD Medical (Revised Segment): Now includes the Medication Delivery Solutions unit, incorporating BD's former Medication and Procedural Solutions unit alongside Bard's oncology and urology products (e.g., PICCs, acute dialysis).
Supplemental unaudited historical combined financial information is provided in Exhibit 99.1, adjusting for divestitures (Respiratory Solutions, Simplest, spine, and specific Bard product lines) and intercompany revenue eliminations.
Material Changes Versus Prior Period
The primary material change is the consolidation of Bard into BD's financial reporting and the realignment of product lines across segments. The filing introduces "foreign currency-neutral" growth metrics to eliminate exchange rate fluctuations when comparing fiscal 2016 to 2017 adjusted comparable revenues. No specific numerical growth rates or profit margins are disclosed in the text of this filing.
Guidance, Outlook, and Risks
Management states that the adjusted comparable revenue measure is intended to facilitate comparisons of the combined company's results against prior periods and to aid in understanding revenue guidance for fiscal 2018. The filing includes significant disclaimers:
- The supplemental financial information is unaudited and prepared for illustrative purposes only.
- It does not fully conform to BD's accounting policies.
- It is not indicative of actual operating results that would have occurred if the acquisition had been consummated earlier, nor does it predict future results.
- The information should not be viewed as a replacement for GAAP results or future pro forma statements required by the SEC.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific numerical values of adjusted comparable revenues and the reconciliation to GAAP revenues.
- Verify the exact scope of products moved between the new BD Interventional and BD Medical segments.
- Confirm the impact of the divestitures (Respiratory Solutions, Simplest, spine, and Bard's Aspira line) on the adjusted revenue figures.
- Check subsequent filings for the official pro forma financial statements required by SEC regulations.
- Monitor the second fiscal quarter 2018 Form 10-Q for the first official reporting under the new segment structure.